MedTrace Logo

Safety and Immune Response to FMPV-1

NCT05238558 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-09-21

No results posted yet for this study

Summary

This is a single centre, open-label, non-randomized, Phase I study assessing safety and immune response of FMPV-1 in healthy male subjects.

Conditions

Interventions

BIOLOGICAL

FMPV-1

Intradermal administration

BIOLOGICAL

GM-CSF (as adjuvant)

Intradermal administration

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • Hubro Therapeutics AS

    lead INDUSTRY

Principal Investigators

  • Nand Singh · Quotient Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2022-10-31
Completion
2023-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238558 on ClinicalTrials.gov